1 經濟部工業局陳昭蓉副組長工研院生醫所邵耀華所長 2016年 8月 10日從政府規劃的角度看臺灣生醫產業的現況與展望

從政府規劃的角度看臺灣生醫產業的現況與展望hidas-learning.weebly.com/uploads/4/6/2/0/46204475/...從政府規劃的角度看臺灣生醫產業的現況與展望

Download PDF Report

Upload
others
View
6
Download
0

Embed Size (px)

Citation preview

1

2016 8 10
2
()

()

()()()

3
2016

4
%

()

201418.4%20201.4

IMS, 2015

5
()

%

Espicom BM201620165

20153,23920183,825

48.8%23.8%

6
2016

20152,986 8% 7% 7.5%

()

538 606

665 677 717 823 841

936 979 1022

1177 1,600

1,791 1,912

2,010 2,105

2,286 2,403

2,630 2,769

2,886 2986

1,133

1,332 1,374 1,435 1,483

1,610

1,845

2,035 2,092 2,114

2241 1,156 1,136 1,116

1,184

1,300 1,355

1,428 1,505

1,601 1,631

1871

0

200

400

600

800

1,000

1,200

1,400

1,600

1,800

2,000

0

500

1,000

1,500

2,000

2,500

3,000

3,500

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

()

7
(

)

2015484.9320145.8%

49%45%6%

2016

()

88.9 95.01 74.14 102.13 109.21

53.73 54.58 104.99

68.87 93.32 86.36

111.23 78.23 136.21 110.81 83.96

130.21

200.18

167.63 221.13 184.33 207.92

52.88

36.88

59.55 37.54 69.63 117.23

78.4

122.7 130.35

180.62 190.65

253.01

210.12

269.9 250.48

262.8

301.17

333.16

395.32 420.35

458.27 484.93

0

100

200

300

400

500

600

2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015

8
()

IND

NDA

Eurofins Panlabs, Inc ()

BA/BE

123PIC/s GMP 21GMP 16 33 (TFDA, 2016/Mar./28)

95GMP

CRO

,,,(),,,,, ( ). , , , , , , , .

: IND: Investigation of New Drug, NDA: New Drug Application, CRO: Contract Research Organization, :

// / ////

/

/

(505(b)(2))

/

//////////////////

/// /// /////

/*/*/*/*/*/* /*// ////* *

9
() X :

,,,,,,, ,,,, ,,IC,

()

/ / /

IEK

R&D

10
()

201595

2016

5

F-F-PG() F-15

20022002 20168

()99

8

1

2

0 0

1 1 1

3 3 3 3

0

2

0

9

5

8

3

1

2

3 3 3

7

10

9

5 5 5

9

13

8

1

0

4

9 9

16

12

17

11

17

15 15

0

2

4

6

8

10

12

14

16

18

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

11
201320132012

20161

20151,895201418%

201512318,428

19100(F-F-F*F-)

468.12 471.28 518.51 668.09 771.41

980.36

1,434.26 1,593.68 1,895.72

1,154.24 818.76

1,748.93

2,188.47 2,199.30

4,237.08

6,291.24 6,377.61

8,428.59

37 40

44 48

58

71

83

88

95

0

10

20

30

40

50

60

70

80

90

100

0

1000

2000

3000

4000

5000

6000

7000

8000

9000

2007 2008 2009 2010 2011 2012 2013 2014 2015

()

8,400

12
8

2005/06

2010/04 PG2

2011/12 OTC

2013/03

2014/02

2014/03

2015/01

2015/10

ITIS2016

()

13
()

X

14
20205,000

3

5 () / 20

2,886

4,093

5,112

2,900

3,400

4,400

5,400

2014 2020

1,000

6%

10%

15
10~100

/

/()

1000

16
http://www.google.com.tw/url?url=http://www.lyons.com/medical_device_solutions_LLC/&rct=j&frm=1&q=&esrc=s&sa=U&ei=m_RyVN6PAZPl8AXuj4GYAw&ved=0CBUQ9QEwADhk&usg=AFQjCNFJWa0vEcM39kRSfmcb_Vy9xcFo5Qhttp://www.google.com.tw/url?url=http://techonomy.com/2012/09/why-drug-development-is-failing-and-how-to-fix-it/&rct=j&frm=1&q=&esrc=s&sa=U&ei=oPVyVK30F4qa8QX5q4HYCA&ved=0CCEQ9QEwBjgo&usg=AFQjCNGs8PDoLcLQZRBbiwmnp4iJ1tQ29whttp://www.google.com.tw/url?url=http://www.korten.in/pharmaceuticals.php&rct=j&frm=1&q=&esrc=s&sa=U&ei=5HXIU6aAF9Tp8AX2zoKQCQ&ved=0CBUQ9QEwAA&usg=AFQjCNHzC9cqpVdzEI_tSPtc3VB90_UQpA
ICT

m-Health (X//MRI)

/

//

/

/

total solution

//

ICT

17
class II

IVD /

IVDTotal Solution

- (Brand

Generic)

18
/

/

BDL/IEK

()

()

19
()

20
/

//

/

/

/

/

21
/()

() ()

TPM)

()

22
3

2

32

101122

32

201621 2016219 20166

201622421 2016226

2

1.

2.

23
A+

(SBIR)

24
20168

20166102240

801951529716

30

80 195 9

16 29 17

7 16 4

102 240 30

102

25
()36

2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016

20168

36

26
X MRI

10550(1025.69)

;X;

MRI

15(2.9)

584

SwissRay

X

i5DR

ddRCruze

ddRFormula

Branding Taiwan

/

X

003931004297004298

FDA510(k)(2013) CE(2014)

2015 004882

-

27
1.18

2.938.33

-

28
29
30